We invest in European and Israeli HealthTech startups once an initial MVP can be tested by potential customers, while being open to building relationships at earlier stages. Pre-revenue companies are considered in some cases, though as a rule of thumb we like to see around €300K in revenue.
The summary is based on the profile data provided by the investor
followed by: